Dr Ramesh Byrapaneni breaks down his investment rationale for Synapsica.“My belief is that technology, would not do away with specialized manpower, what it aims to do is further strengthen and empower the abilities and decision-making for the specialists.” He says.Read on to know what fuels a strong decision to partner and invest.
Sateesh says “Our decision to invest in Upside AI was driven by the fact that the founders had the vision that questioned the normal and sought to better it, and at the same time build a radical solution to address an existing gap in the PMS/AMC Space.
Dr Ramesh Byrapaneni says" I believe that the time for cell therapy solutions has arrived and the starting point to this promising area of science has to be the eye, the retina, to be specific. Eyestem intends to disrupt the global cell therapy ecosystem and set a new benchmark for quality and affordability in this sector. Eyecyte-RPE, their flagship solutions to treat incurable age related macular degeneration has excellent efficacy results and will be in 'First in Man' (FIM) trials in 2021."
Sateesh breaks down his thoughts and helps you understand why the comparison "Moore's Law, from the world of computing, refers to the number of transistors on a microchip doubling every two years, though the cost of computers is halved. Interestingly, the law and the multiplier effect at its core have been relevant across multiple sectors in the past. A great example at hand and still unfolding is the vibrant Indian venture capital and entrepreneurial ecosystem"
